Negative Neurofilament Light and Tau Immunostaining in Frontotemporal Dementia

  title={Negative Neurofilament Light and Tau Immunostaining in Frontotemporal Dementia},
  author={Magnus Sj{\"o}gren and Elisabet Englund},
  journal={Dementia and Geriatric Cognitive Disorders},
  pages={346 - 349}
We investigated the immunohistochemical stainability of phosphorylated tau and the light (NFL), intermediate (NFM), and heavy (NFH) neurofilament proteins in postmortem brain tissue from 8 patients with frontotemporal dementia (FTD), for comparison with 6 patients with Alzheimer’s disease (AD), and 6 normal controls. In the FTD group, the neuropathological diagnosis was pure frontal-lobe degeneration of non-Alzheimer type (FLD) in 6 cases and in the remaining 2 cases mixed FLD-AD and frontal AD… Expand
4 Citations
Pharmacogenomics in Alzheimer's disease.
Functional genomics studies in AD revealed that age of onset, brain atrophy, cerebrovascular hemodynamics, brain bioelectrical activity, cognitive decline, apoptosis, immune function, lipid metabolism dyshomeostasis, and amyloid deposition are associated with AD-related genes. Expand
RNA-binding protein is involved in aggregation of light neurofilament protein and is implicated in the pathogenesis of motor neuron degeneration.
It is reported that p190RhoGEF, an RNA-binding protein that binds to a destabilizing element in NF-L mRNA, is involved in aggregation ofNF-L protein and is implicated in the pathogenesis of motor neuron degeneration and siRNA-induced down-regulation of p 190Rho GEF causes reversal of aggregation and recovery of NF assembly in transfected cells. Expand
Geriatric psychiatry Advances and debates in geriatric psychopharmacology
  • 2005
Amison T, Foster A. Electroconvulsive therapy in a middle-aged adult with cortical atrophy. J ECT 2005; 21:122–124. Bennett DA, Holtzman DM. Immunization therapy for Alzheimer disease? NeurologyExpand
Pharmacogenomics in Drug Discovery and Development
  • Qing Yan
  • Medicine
  • Methods in Molecular Biology™
  • 2008


Cytoskeleton proteins in CSF distinguish frontotemporal dementia from AD
A differential involvement of these cytoskeleton proteins inFTD and EAD is suggested, with NFL primarily involved in the pathophysiology of FTD and tau in that of EAD. Expand
Biochemical and Molecular Characterization of Neurofibrillary Degeneration in Frontotemporal Dementias
  • A. Delacourte
  • Medicine, Biology
  • Dementia and Geriatric Cognitive Disorders
  • 1999
The biochemical signature of tau distinguishes four classes of frontotemporal dementia, and the characteristic tau phenotypes observed are linked to the specific neuronal networks that are affected in each disease. Expand
Tau and neurofilaments in a family with frontotemporal dementia unlinked to chromosome 17q21–22
Analysis of Tau and neurofilament modifications in a Swiss frontotemporal dementia kindred with extrapyramidal-like features and without motor neuron disease indicates that tau is not at the origin of FTD in this family. Expand
Frontotemporal dementia: Neuropil spheroids and presynaptic terminal degeneration
The central nervous systems of FTD patients are distinguishable from those of other patients with other lobar dementias, including Pick's disease and corticobasal degeneration, by the absence of abnormally phosphorylated neuronal or glial tau inclusions. Expand
Familial frontotemporal dementia with ubiquitin-positive, tau-negative inclusions
This family with autosomal dominant frontotemporal dementia (FTD) shows no tau expression in neurons, and some pathologic features are similar to those of several of the families included in descriptions of FTD with parkinsonism linked to chromosome 17, but the linkage to tau has been excluded. Expand
Neurofilament proteins NF-L, NF-M and NF-H in brain of patients with Down syndrome and Alzheimer's disease
It is suggested that NFs are not reliable markers for neuronal death, a hallmark of both neurodegenerative diseases, in DS or AD. Expand
Selective reduction of soluble Tau proteins in sporadic and familial frontotemporal dementias: an international follow-up study
The definition of DLDH is extended as a sporadic or familial "tau-less" tauopathy with reduced levels of soluble brain tau and no insoluble tau or fibrillary tau inclusions, and the data also underline the phenotypic heterogeneity of HDDD2, which parallels the phenotypesIC heterogeneity of other hereditary neurodegenerative FTD tauopathies caused by tau gene mutations. Expand
Clinic-Based Cases with Frontotemporal Dementia Show Increased Cerebrospinal Fluid Tau and High Apolipoprotein E ε4 Frequency, but No Tau Gene Mutations
The present notion of a common pathogenic pathway in the disease processes for several tauopathies, with both APOE epsilon4 and CSF tau being a pathological link between the different disorders, is supported. Expand
Attenuated Neurodegenerative Disease Phenotype in Tau Transgenic Mouse Lacking Neurofilaments
The results imply that NFs are pathological chaperones in the development of tau spheroids and suggest a role for NFs in the pathogenesis of neurofibrillary tau lesions in neurodegenerative disorders that contain both NFs and tau proteins. Expand
Paired helical filaments from Alzheimer disease patients contain cytoskeletal components.
It is concluded that these epitopes are integral components of the paired helical filaments and that, at least in part, paired helicals filaments are derived from altered elements of the normal neuronal cytoskeleton. Expand